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Prognostic nutritional index (PNI) reflects the nutritional and immunologic status of the
patients. The clinical application of PNI is already well-known in various kinds of solid
tumors. However, there is no study investigating the relationship between PNI and oncologi-
cal outcome of the resected ampulla of Vater (AoV) cancer.
Materials and methods
From January 2005 to December 2012, the medical records of patients who underwent pan-
creaticoduodenectomy for pathologically confirmed AoV cancer were retrospectively
reviewed. Long-term oncological outcomes were compared according to the preoperative
PNI value.
Result
A total of 118 patients were enrolled in this study. The preoperative PNI was 46.13±6.63,
while the mean disease-free survival was 43.88 months and the mean disease-specific sur-
vival was 55.3 months. In the multivariate Cox analysis, initial CA19-9 (p = 0.0399), lympho-
vascular invasion (p = 0.0031), AJCC 8th N-stage (p = 0.0018), and preoperative PNI (p =
0.0081) were identified as significant prognostic factors for resected AoV cancer. The dis-
ease-specific survival was better in the high preoperative PNI group (�48.85: 40.77 months
vs. >48.85: 68.05 months, p = 0.0015). A highly accurate nomogram was developed based
on four clinical components to predict the 1, 3, and 5-year disease-specific survival probabil-
ity (C-index 0.8169, 0.8426, and 0.8233, respectively).
Conclusion
In resected AoV cancer, preoperative PNI can play a significant role as an independent
prognostic factor for predicting disease-specific survival.
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Introduction
Primary ampulla of Vater (AoV) cancer only occurs in 4 to 6 cases per million population, but
it is responsible for 20% of all tumor-related obstructions of the common bile duct. The inci-
dence of this cancer has increased over the last 30 years [1, 2]. Patients undergoing pancreati-
coduodenectomy (PD) for AoV cancer have a 5-year disease-free survival of approximately
65%, and the 5-year disease-specific survival varies from 33.3% to 59.9% [3–6]. These results
indicate a better prognosis than that in other types of periampullary cancers. As far as recent
studies are concerned, the independent factors deciding AoV cancer outcomes are AJCC T/N
staging [3–6], R-status [3, 4], tumor differentiation [1, 3–5], pathological tumor size [1, 5], Dif-
ferent histopathologic [7], perineural invasion [8], tumor budding [9] and extranodal exten-
sion of nodal metastasis [10].
Prognostic nutritional index (PNI) is an indicator of the nutritional and immunologic status
of the patients [11, 12]. Recently, multiple studies have demonstrated its correlation with post-
operative complications and cancer outcomes in various kinds of solid organ cancer, such as
gastric cancer [13], small cell lung cancer [14], non-small cell lung cancer [15], ovarian cancer
[12], pancreatic cancer [16, 17], colorectal cancer [18], hepatocellular carcinoma [19–21],
esophageal cancer [22], and renal cell carcinoma [23]. However, there is no specific study inves-
tigating the potential relationships between PNI and AoV cancer. Therefore, in this study, we
investigated the potential oncological impact of preoperative PNI on resected AoV cancer.
Materials and methods
Patients
This was a retrospective study involving patients who underwent PD at Severance Hospital,
Seoul, Korea, between January 2005 and December 2012. Only patients with pathologically
confirmed AoV adenocarcinoma were enrolled in our study. The medical records and demo-
graphic characteristics of the patients were retrospectively reviewed from the electrical medical
record (EMR). All data were fully anonymized before assessment and were kept on saving
materials under restricted access for only authorized clinicians. The present study has waived
the requirement for informed consent because of minimal risk (level I) and approved by the
institutional review board (IRB) of Severance Hospital at Yonsei University College of Medi-
cine (IRB no. 4-2019-0379).
Preoperative and intraoperative measurements
Data on initial CA 19–9, initial total bilirubin, preoperative total bilirubin, albumin, lympho-
cyte count, and liver functions were collected and each PNI was calculated from the preopera-
tive results [albumin (g/dL) × 10 + preoperative lymphocytic count × 0.005] [11]. In our study,
adjusted preoperative CA 19–9 (serum CA 19–9 divided by serum total bilirubin) were applied
as CA 19–9 level could be elevated from biliary obstruction, which could be helpful to reduce
bias and to estimate true value of CA 19–9 [24–26].
Radiological tumor size and preoperative biliary drainage procedure were checked as each
of them was known as associated with postoperative surgical outcome [27, 28]. The operation
type, operation time, intraoperative estimated blood loss, and transfusion history were
reviewed as covariates.
More than 90% of the patients had the operation in 6wks from the first diagnosis, and the
average time from diagnosis to the operation was 18.5 days. During this period patients went
further cancer evaluation and were treated for preoperative general conditions like jaundice or
cholangitis.
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Pathological and postoperative outcomes
Data regarding the pathological tumor size, total number of retrieved lymph nodes, number of
metastatic lymph nodes, AJCC 8th TNM, perineural invasion, lymphovascular invasion, tumor
differentiation, tumor gross type, R-status, and histological types were collected and examined
by pathologists. The details of postoperative complications severe than Clavien-Dindo grade
IIIa, postoperative pancreatic fistula (POPF) [29, 30], and adjuvant chemotherapy were col-
lected. Adjuvant chemotherapy was selectively done under clinician’s decision in patients with
advanced stages like AJCC 8th T stage higher than T2, positive lymph nodes, R1 resection, or
positive perineural invasion. Long-term oncological outcomes were investigated, including
disease-free survival (the duration after the pancreaticoduodenectomy to the date of diagnosis
of recurrent AoV cancer) and disease-specific survival (the duration from the pancreaticoduo-
denectomy to the time of death from AoV cancer).
Statistical analyses
The continuous variables were expressed as the mean ± standard deviation, and the categorical
variables were expressed as the frequency (%). Student’s t-test was performed with the contin-
uous variables which were normally distributed, and Mann-Whitney U test used for the con-
tinuous variables which were not normally distributed. Chi-square test or Fisher’s extract test
was used for the categorical variables.
To evaluate oncologic outcomes and survival analysis, the selection of statistically signifi-
cant variables (p<0.05) was done, following univariate Cox regression test. These variables
underwent multivariate Cox regression analysis to evaluate oncologic outcomes. Backward
elimination used for final multivariate Cox regression results. Also Kaplan Meier survival anal-
ysis and log-rank test methods were used for survival analysis. [31–33]
For evaluating the discrimination of the predictive model, Harrell’s c-index was used for
the nomogram model. The c-index and 95% confidence interval (CI) were shown after 10,000
times of bootstrap resampling. The proximity between the estimated and actual value was visu-
ally inspected with a calibration plot. The goodness of fit test was performed with GND
(Greenwood-Nam-D’Agostino) test [34]. The cut-off value of PNI and CA 19–9 were calcu-
lated based on the Contal and O’quigley’s method [35–37]. SPSS Statistics version 23 was used
for the analyses.
Results
General characteristics of the patients
A total of 118 patients were included in the study. Table 1 describes the demographic charac-
teristics of the patients (Table 1). There were 64 males and 54 females with a mean age of
61.1 ± 10.2 years. The mean follow-up period was of 53.3 ± 34.3 months. A total of 69 patients
(58.5%) survived, 49 patients (41.5%) died, and 77 patients (65.3%) received postoperative
adjuvant chemotherapy.
Fig 1 describes the distribution of preoperative PNI in the resected AoV cancer. The PNI
was 46.13 ± 6.63 (median, 45.8) (Fig 1).
Survival analysis in resected AoV cancer
The mean disease-free survival was found as 43.88 months, (95% CI, 38.49−49.27) and the
mean disease-specific survival was 55.3 months (95% CI, 50.53−60.05). In disease-specific sur-
vival, Table 2 shows the baseline characteristics and univariable Cox regression analysis for
predicting cancer-related death in the resected AoV cancer (Table 2). The left side of the table
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shows baseline characteristics. Student’s t-test was done in continuous variables which fit nor-
mal distribution and Mann-Whitney U test was done in continuous variables which didn’t fit
normal distribution. Categorical variables were analyzed with Chi-square test or Fisher’s exact
test (Table 2, Left side of the table). Univariable Cox regression analysis was done in these vari-
ables (Table 2, Right side of the table).
Among the preoperative factors, adjusted initial CA19-9 of�53.19 (p = 0.0015), initial/pre-
operative total bilirubin (p = 0.0003, p = 0.0028 respectively), and preoperative PNI of�48.85
Table 1. Demographic characteristics of the patients.
Total N = 118 (%)
Gender
Male N = 64 (54.2)
Female N = 54 (45.8)
Age (Year) 61.13 ± 10.23
Follow-up (Month) 53.3 ± 34.31
Initial CA 19–9 (U/mL) (Adjusted) 499.41 ± 2147.24
Initial T.bil (mg/dL) 4.45 ± 5.40
Pre-OP T.bil (mg/dL) 1.70 ± 1.78
Pre-OP CEA (ng/mL) 2.44 ± 2.36
Pre-OP Bile drainage N = 70 (59.3%)
PTBD N = 12 (17.1%),
ENBD N = 5 (7.1%),
ERBD N = 51 (72.9%)
Dual manner� 2 (2.9%)
OP method
Open N = 109 (92.4%)
Laparoscopic N = 9 (7.6%)
Subtype
Pancreatobiliary type N = 63 (53.4%)
Intestinal type N = 55 (46.6%)
Pathological T-stage
Tis N = 2 (1.7%)
1a/1b N = 7/30 (5.9%/25.4%)
2 N = 32 (27.1%)
3a/3b N = 19/28 (16.1%/23.7%)
Pathological N-stage
N0 N = 76 (64.4%)
N1 N = 23 (19.5%)
N2 N = 19 (16.1%)
Survival
Survival N = 69 (58.5%)
Death N = 49 (41.5%)
Adjuvant Chemotherapy
Yes N = 77 (65.3%)
No N = 41 (34.7%)
CA 19–9, carbohydrate antigen 19–9; OP, operation; CEA, carcinoembryonic antigen; PTBD, percutaneous
transhepatic biliary drainage; ENBD, endoscopic nasobiliary drainage; ERBD, endoscopic retrograde bile drainage
�PTBD followed by ERBD, ERBD followed by ENBD each.
https://doi.org/10.1371/journal.pone.0229597.t001
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(p = 0.0029) were noted as significant variables. The number of positive metastatic lymph
node was found as a significant variable among the intraoperative factor in predicting the sur-
vival (p<0.0001). Among the postoperative factors, it was found that perineural invasion
(p = 0.0003), lymphovascular invasion (p = 0.0023), subtype of tumor (p = 0.0059), tumor
grade (p = 0.0176), AJCC 8th T/N-stage (p = 0.0217, p = 0.0001 each), postoperative adjuvant
chemotherapy (p = 0.0028), and recurrence (p =<0.0001) were significant [1, 3–6].
Preoperative PNI as an independent prognostic factor
Multivariate Cox analysis was used to predict the significant prognostic factors in resected
AoV cancer (Table 3). Adjusted initial CA 19–9 [HR = 1.954 (95% CI, 1.031−3.701),
p = 0.0399], lymphovascular invasion [HR = 2.775 (95% CI, 1.412−5.452), p = 0.0031], AJCC
8th N stage [N-Stage 1: HR = 3.282 (95% CI, 1.553−6.932), p = 0.0018; N-Stage 2: HR = 4.978
(95% CI, 2.122−11.676), p = 0.0002, respectively], and PreOP-PNI [HR = 0.300 (95% CI, 0.123
−0.732), p = 0.0081] were identified as important factors for disease-specific survival in
resected AoV cancer.
It was estimated that the disease-free survival was different according to the preoperative
PNI with a marginal significance [�48.85: 21.75 months (95% CI, 19.03−24.4) vs.>48.85:
51.88 months (95% CI, 43.10−60.66), p = 0.0633, Fig 2A]. However, significant difference
showed in disease-specific survival according to preoperative PNI [�48.85: 40.77 months
(95% CI, 36.28−45.26), vs. <48.85: 68.05 months (95% CI, 63.02−73.06) p = 0.0015, Fig 2B].
Survival analyses at PNI high/low group under stratification was done to evaluate if PNI
correlates with disease status and to exclude bias from our study (Table 4.). However it showed
Fig 1. Distribution of the preoperative PNI in resected AoV cancer.
https://doi.org/10.1371/journal.pone.0229597.g001
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Table 2. Baseline characteristics and univariate Cox regression analysis for predicting cancer-related death in resected AoV cancer. (Left column: Baseline character-
istics, Right column: univariate Cox regression analysis).
Variables Survival N = 77 Death N = 41 p-value HR Lower Upper p-value
Age 62 (54 −67) 66 (57 −70) 0.0747 1.031 0.996 1.067 0.0835
Gender Male 40 (51.95) 24 (58.54) 0.4940 1 (ref)
Female 37 (48.05) 17 (41.46) 0.745 0.400 1.386 0.3526
BMI (kg/m2) 23.44±2.91 22.95±2.5 0.3689 0.941 0.844 1.050 0.2766
Initial CA19-9 (U/mL) (cut-off)
��
(Adj.) $ $ <53.19 55 (71.43) 17 (42.46) 0.0015� 1 (ref)
�53.19 22 (28.57) 24(58.54) 1.954 10.31 3.701 0.0399�
Initial total bilirubin (mg/dL) 1.50 (0.60 −4.10) 5.30 (1.60 −10.60) 0.0003� 1.079 1.041 1.118 < .0001�
PreOP total bilirubin (mg/dL) 0.80 (0.50 −1.80) 1.60 (0.90 −2.70) 0.0028� 1.140 1.006 1.292 0.0394�
Radiologic tumor size (mm) 20 (14 −25) 20 (15 −25) 0.4808 0.997 0.966 1.029 0.8511
PreOP-PNI (cut-off)
��
PNI�48.85 45 (58.44) 35 (85.37) 0.0029� 1 (ref)
PNI >48.85 32 (41.56) 6 (14.63) 0.270 0.113 0.643 0.0031�
PreOP-biliary drainage No 36 (46.75) 12 (29.27) 0.0656 1 (ref)
Yes 41 (53.25) 29 (70.73) 2.031 1.036 3.983 0.0392�
Operation method Open 69 (89.61) 40 (97.56) 0.1595 1 (ref)
Lapa 8 (10.39) 1 (2.44) 0.226 0.031 1.648 0.1425
Operation time (min) 390 (328 −460) 409 (362 −487) 0.3268 1.002 0.999 1.004 0.2501
Estimated blood loss (ml) 400 (200 −700) 500 (200 −900) 0.3865 1.000 1.000 1.001 0.1483
Transfusion No 63 (81.82) 32 (78.05) 0.6226 1 (ref)
Yes 14 (18.18) 9 (21.95) 1.034 0.493 2.167 0.9295
Number of total retrieved LNs 19 (11 −29) 19 (11 −28) 0.9459 1.001 0.979 1.022 0.9559
Number of positive LNs 0 (0 −0) 2 (0 −4) <0.0001� 1.212 1.129 1.302 < .0001�
Pathologic tumor size (mm) 20 (15 −27) 20 (17 −25) 0.6931 0.995 0.966 1.024 0.7211
Complication No 30 (38.96) 11 (26.83) 0.1876 1 (ref)
Yes 47 (61.04) 30 (73.17) 1.619 0.811 3.231 0.1719
POPF No 45 (58.44) 24 (58.54) 0.0841 1 (ref)
Grade A 22 (28.57) 6 (14.63) 0.554 0.226 1.356 0.1958
Grade B 10 (12.99) 10 (24.39) 1.811 0.865 3.792 0.1151
Grade C 0 (0) 1 (2.44) 2.133 0.288 15.787 0.4583
R-status R0 75 (97.4) 39 (95.12) 0.6092 1 (ref)
R1 2 (2.6) 2 (4.88) 2.175 0.522 9.059 0.2856
Perineural invasion No 71 (92.21) 27 (65.85) 0.0003� 1 (ref)
Yes 6 (7.79) 14 (34.15) 3.141 1.640 6.017 0.0006�
Lymphovascular invasion No 66 (85.71) 25 (60.98) 0.0023� 1 (ref)
Yes 11 (14.29) 16 (39.02) 3.758 1.993 7.088 < .0001�
Subtype PB 34 (44.16) 29 (70.73) 0.0059� 1 (ref)
Int. 43 (55.84) 12 (29.27) 0.341 0.173 0.671 0.0018�
Gross type Polypoid 51 (66.23) 27 (65.85) 0.8411 1 (ref)
Ulcerative 14 (18.18) 7 (17.07) 0.922 0.403 2.110 0.8481$
Mixed 2 (2.6) 0 (0) 0.918 0.052 16.154 0.9531$
Unknown 10 (12.99) 7 (17.07) 1.369 0.599 3.132 0.4565$
Tumor grade Well 34 (44.16) 8 (19.51) 0.0176� 1 (ref)
Moderate 40 (51.95) 30 (73.17) 2.733 1.249 5.978 0.0118�
Poor 3 (3.9) 3 (7.32) 7.286 1.900 27.942 0.0038�
T-stage (AJCC 8th) IA 8 (10.39) 1 (2.44) 0.0217� 1 (ref)
IB 25 (32.47) 5 (12.2) 1.743 0.204 14.920 0.6121
II 20 (25.97) 12 (29.27) 4.469 0.581 34.382 0.1504
(Continued)
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no difference of important factors for disease-specific survival in resected AoV cancer even
after stratify with high/low PNI group (Initial CA19-9, Lymphovascular invasion, AJCC 8th N
stage at common) (Table 5.).
Statistical analysis of disease free-survival is noted on S1 and S2 File. S2 File is the analysis
of disease free survival after PNI stratification. S1 File showed that adjusted CA 19–9, preoper-
ative T.bilirubin positive lymph node number and subtype of adenocarcinoma were relevant
with oncologic survival. S2 File showed adjusted initial CA 19–9, the subtype of adenocarci-
noma, and AJCC 8th N stage had statistical significance to disease free survival after PNI
stratification.
Developing nomogram to predict cancer-specific survival
Based on the significant independent variables, such as adjusted initial CA 19–9, lymphovascu-
lar invasion, AJCC N-stage, and preoperative PNI, a nomogram for predicting the 1, 3, and
5-year survival probability in resected AoV cancer was developed (Fig 3).
Table 2. (Continued)
Variables Survival N = 77 Death N = 41 p-value HR Lower Upper p-value
IIIA 11 (14.29) 8 (19.51) 5.288 0.661 42.321 0.1166
IIIB 13 (16.88) 15 (36.59) 8.274 1.090 62.793 0.0410�
N-stage (AJCC 8th) N0 60 (77.92) 16 (39.02) 0.0001� 1 (ref)
N1 9 (11.69) 14 (34.15) 4.335 2.099 8.954 < .0001�
N2 8 (10.39) 11 (26.83) 7.770 3.518 17.159 < .0001�
Postop-adjuvant chemotherapy No 52 (67.53) 16 (39.02) 0.0028� 1 (ref)
Yes 25 (32.47) 25 (60.98) 2.303 1.227 4.324 0.0094�
Recurrence No 62 (80.52) 7 (17.07) < .0001� 1 (ref)
Yes 15 (19.48) 34 (82.93) 14.558 6.244 33.943 < .0001�
HR, hazard ratio; BMI, body mass index; PreOP, preoperative; LN, lymph node; PNI, prognostic nutritional index; POPF, postoperative pancreatic fistula; PB,
pancreatobiliary type; Int., intestinal type.
�p-value <0.05
��Cut off value deducted from the Contal and O’quigley’s method [35–37].
$Using firth bias correction for the estimation of 95% CI [38].
$ $Adj. = Adjusted
https://doi.org/10.1371/journal.pone.0229597.t002
Table 3. Multivariate Cox analysis for predicting the disease-specific survival in resected AoV cancer.
Variables Death (0: survival, 1: death)
HR Lower Upper p-value
Initial CA19 (U/mL) (Adjusted) 0: CA19 <53.19 1 (ref)
1: CA19�53.19 1.954 1.031 3.701 0.0399
Lymphovascular invasion 0: No 1 (ref)
1: Yes 2.775 1.412 5.452 0.0031
AJCC8_Nstage 0: No 1 (ref)
1: N1 3.282 1.553 6.932 0.0018
2: N2 4.978 2.122 11.676 0.0002
PreOP-PNI 0: PNI�48.85 1 (ref)
1: PNI >48.85 0.300 0.123 0.732 0.0081
https://doi.org/10.1371/journal.pone.0229597.t003
PLOS ONE Oncologic impact of preoperative prognostic nutritional index in ampulla of Vater cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0229597 March 3, 2020 7 / 15
Model performance and calibration
The performance of the nomogram was assessed with Harrell’s C-index (Table 6). The c-index
and 95% CI were shown after 10,000 times of bootstrap resampling. Every single average C-
index was noted to be>0.80 with a narrow confidence interval suggesting that the currently
developed nomogram model was highly predictive.
The calibration plot was made by comparing the predictive value with the real value. Con-
sidering that approximation with the 45-degree oblique dotted line estimates better results, the
present calibration plot suggests that our nomogram has an acceptable accuracy in predicting
the survival in resected AoV cancer (Fig 4).
Discussion
In cancer patients, it is well known that the nutritional status is a conclusive independent fac-
tor for the postoperative outcomes [12]. In addition, nutrition correlates with general immu-
nological functions and internal metabolisms. One commonly used indicator for nutrition is
the PNI, which is calculated by using two clinical variables: preoperative albumin and lympho-
cytic count in the blood [11]. Recently, multiple studies have shown that preoperative PNI is a
good predictive factor for estimating cancer outcome after cancer surgery [11], such as gastric
cancer [13], esophageal cancer [22], hepatocellular cancer [19–21], pancreatic cancer [16, 17],
colorectal cancer [18], renal cell carcinoma [23], non-small cell lung cancer [15], and small cell
lung cancer [14].
TNM staging, recurrence, pathological tumor size, and tumor differentiation are the factors
for predicting the postoperative oncological outcome of resected AoV cancer [1, 3–6]. Till
now, no study has reported the potential oncological impact of preoperative PNI in resected
AoV cancer. In this study, it has been successfully demonstrated that there is a potential associ-
ation between the preoperative PNI and the long-term oncological outcome in resected AoV
cancer. In this study, in the univariate analysis, the adjusted initial CA19-9 of�53.19, initial/
preoperative total bilirubin, preoperative PNI of�48.85, number of positive metastatic lymph
nodes, perineural invasion, lymphovascular invasion, subtype of the tumor, tumor grade,
AJCC 8th T/N-stage, postoperative adjuvant chemotherapy, and recurrence were identified as
Fig 2. Long term oncological outcomes according to the preoperative PNI in resected AoV cancer. (A) Disease-free
survival. (B) Disease-specific survival.
https://doi.org/10.1371/journal.pone.0229597.g002
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Table 4. Univariate Cox analysis for predicting the disease-specific survival in resected AoV cancer. (PNI group stratification).
Variables Low group N = 80 High group N = 38 p-value HR Lower Upper p-value
Age 62 (56–69) 59 (51–66) 0.034� 1.019 0.985 1.055 0.279
Gender Male 47 (58.8) 17 (44.7) 0.219 1 (ref)
Female 33 (41.3) 21 (55.3) 0.883 0.504 1.548 0.664
BMI (kg/m2) 22.86±2.65 24.14±2.85 0.018� 0.973 0.870 1.089 0.639
Initial CA19-9 (U/mL) (cut-off)
��
(Adj.) $ $ <53.19 42(52.5) 30(78.9) 0.011� 1 (ref)
�53.19 38(47.5) 8(21.1) 2.643 1.503 4.649 0.001�
Initial total bilirubin (mg/dL) 5.52 (1.67–9.37) 2.21 (1.31–3.11) <0.001� 1.062 1.023 1.102 0.002�
PreOP total bilirubin (mg/dL) 2.05 (1.00–3.10) 0.97 (0.67–1.27) 0.001� 1.035 0.938 1.227 0.304
Radiologic tumor size (mm) 21 (16–26) 20 (15–26) 0.568 0.995 0.963 1.028 0.761
PreOP-biliary drainage No 24(30.0) 24(63.2) 0.001� 1 (ref)
Yes 56(70.0) 14(36.8) 1.453 0.812 2.598 0.208
Operation method Open 77(96.3) 32(84.2) 0.030� 1 (ref)
Lapa 3(3.8) 6(15.8) 0.183 0.025 1.323 0.092
Operation time (min) 406 (356–457) 423 (347–500) 0.584 1.002 0.999 1.004 0.183
Estimated blood loss (ml) 550 (256–844) 538 (263–813) 0.906 1.000 1.000 1.001 0.137
Transfusion No 62(77.5) 33(86.8) 0.343 1 (ref)
Yes 18(22.5) 5(13.2) 1.017 0.520 1.991 0.960
Number of total retrieved LNs 23 (15–31) 20 (9–31) 0.235 1.000 0.978 1.023 0.971
Number of positive LNs 2 (1–4) 0 (0–0) 0.132 1.183 1.101 1.271 <0.001�
Pathologic tumor size (mm) 23 (18–28) 22 (15–29) 0.768 0.992 0.963 1.021 0.584
Complication No 32(40.0) 9(23.7) 0.125 1 (ref)
Yes 48(60.0) 29(76.3) 1.128 0.626 2.032 0.688
POPF No 53(66.3) 16(42.1) <0.001� 1 (ref)
Grade A 9(11.3) 19(50.0) 0.817 0.398 1.677 0.582
Grade B 18(22.5) 2(5.3) 1.379 0.652 2.916 0.400
Grade C 0(0) 1(2.6) 3.635 0.487 27.127 0.208
R-status R0 76(95.0) 38(100.0) 0.304 1 (ref)
R1 4(5.0) 0(0) 2.727 0.842 8.834 0.094
Perineural invasion No 64(80.0) 34(89.5) 0.308 1 (ref)
Yes 16(20.0) 4(10.5) 2.584 1.403 4.762 0.002�
Lymphovascular invasion No 59(73.8) 32(84.2) 0.303 1 (ref)
Yes 21(26.2) 6(15.8) 2.531 1.386 4.621 0.003�
Subtype PB 49(61.2) 14(36.8) 0.022� 1 (ref)
Int. 31(38.8) 24(63.2) 0.226 0.115 0.444 <0.001�
Gross type Polypoid 48(60.0) 30(79.0) 0.255 1 (ref)
Ulcerative 17(21.3) 4(10.5) 2.200 0.828 5.846 0.114 $
Mixed 2(2.5) 0(0) 2.000 0.120 33.270 0.629 $
Unknown 13(16.2) 4(10.5) 3.667 1.220 11.021 0.021 $
Tumor grade Well 26(32.5) 16(42.1) 0.535 1 (ref)
Moderate 50(62.5) 20(52.6) 3.333 1.547 7.181 0.002�
Poor 4(5.0) 2(5.3) 9.910 32.05 30.639 <0.001�
T-stage (AJCC 8th) IA 4(5.0) 5(13.2) 0.120 1 (ref)
IB 18(22.5) 12(31.6) 15786.3 0.000 1.246 E+75 0.908
II 20(25.0) 12(31.6) 27052.2 0.000 2.134 E+75 0.902
IIIA 16(20.0) 3(7.8) 48475.2 0.000 3.825 E+75 0.897
IIIB 22(27.5) 6(15.8) 89926.6 0.000 7.092 E+75 0.891
N-stage (AJCC 8th) N0 49(61.2) 27(71.1) 0.247 1 (ref)
(Continued)
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significant variables to predict cancer-related survival, concurrent to previous studies [3–6].
The subsequent multivariate Cox analysis found that preoperative PNI can predict the long-
term survival [HR = 0.300 (95% CI, 0.123−0.732), p = 0.0081] along with other well-known
clinical parameters, such as adjusted initial CA 19–9 (p = 0.0399), lymphovascular invasion
(p = 0.0031), and AJCC 8th N staging (p<0.05). Although there were no significant differences
in the disease-free survival [Preop-PNI of�48.85: 21.75 months (95% CI, 19.03−24.4) vs.
preop-PNI of>48.85: 51.88 months (95% CI, 43.10−60.66), p = 0.0633], it was found that the
higher Preop-PNI group showed a significant positive oncological impact on the disease-spe-
cific survival in resected AoV cancer [40.77 months (95% CI, 36.28−45.26] vs. 68.04 months
(95% CI, 63.02−73.06), p = 0.0015].
These results display that the potentiality of PNI is not inferior to that of the well-known
predictive factors. Further, PNI could play a role as an independent factor influencing the
overall survival. Without pathological confirmation, we can simply calculate PNI from the
basic laboratory results and can predict only with the imaging study. This can be helpful for
preoperative risk assessment and diagnosis of the hazardous group. Though it had no effect on
the disease-free survival, patients who had a higher PNI of 48.85 had a significant benefit on
the disease-specific survival in resected AoV cancer with an HR of 0.300 (p = 0.0081). In addi-
tion, we’ve done stratified survival analyses to evaluate if preOP PNI indicates the advanced
disease stage. In multivariate Cox analysis, there was no difference of statistically significant
variables in disease-specific survival in resected AoV cancer (Adjusted initial CA19-9 HR
0.486, p = 0.030; Lymphovascular invasion HR 2.703, p = 0.004; AJCC 8th N stage N1-HR
3.341, p = 0.002 / N2-HR 4.828, p<0.001).
In addition, preoperative a PNI-based nomogram was developed to calculate the postopera-
tive long-term oncological outcomes in resected AoV cancer. Predicting the power assessed
Table 4. (Continued)
Variables Low group N = 80 High group N = 38 p-value HR Lower Upper p-value
N1 15(18.8) 8(21.1) 4.281 2.141 8.563 <0.001�
N2 16(20.0) 3(7.8) 9.764 4.879 19.540 <0.001�
Postop-adjuvant chemotherapy No 42(52.5) 27(71.1) 0.087 1 (ref)
Yes 38(47.5) 11(28.9) 2.502 1.406 4.453 0.002�
HR, hazard ratio; BMI, body mass index; PreOP, preoperative; LN, lymph node; PNI, prognostic nutritional index; POPF, postoperative pancreatic fistula; PB,
pancreatobiliary type; Int., intestinal type.; E+, exponential
�p-value <0.05
��Cut off value deducted from the Contal and O’quigley’s method [35–37].
$Using firth bias correction for the estimation of 95% CI [38].
$ $Adj. = Adjusted
https://doi.org/10.1371/journal.pone.0229597.t004
Table 5. Multivariate Cox analysis for predicting the disease-specific survival in resected AoV cancer (PNI group stratification).
Variables Death (0: survival, 1: death)
HR Lower Upper p-value
Initial CA19 (Adjusted) (U/mL) 0: CA19 <53.19 1 (ref)
1: CA19�53.19 2.058 1.073 3.937 0.030
Lymphovascular invasion 0: No 1 (ref)
1: Yes 2.703 1.372 5.319 0.004
AJCC8_Nstage 0: No 1 (ref)
1: N1 3.341 1.584 7.047 0.002
2: N2 4.828 2.062 11.308 <0.001
https://doi.org/10.1371/journal.pone.0229597.t005
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with Harrell’s C-index showed PNI-based nomogram works well, and the survival probability
at 1-year, 3-year, and 5-year showed the C-index of>0.80 with a short 95% CI range.
As mentioned before, the most well-known prognostic factors for resected AoV cancer are
mostly determined based on pathological examination after surgical excision. However, sur-
geons or clinicians can easily calculate the preoperative PNI from routine blood laboratory
tests. Therefore, it is anticipated that the present study can be helpful in predicting the postop-
erative long-term oncological outcomes clinically prior to the surgical approach. It suggests
that the oncological outcomes can be modulated by surgeons or clinicians before surgery.
Unlike other prognostic factors, such as adjusted initial CA 19–9, lymphovascular invasion,
and N-stage, preoperative PNI is thought to be affected by patient’s general condition and
nutritional status, which can be improved by appropriate preoperative management, such as
nutritional support or conservative management for improving the general condition.
Although patients with AoV cancers have a typical characteristic that presents a history of
obstructive jaundice, our results showed the growing type of tumor did not have much effect
on preoperative PNI by chronic loss of appetite with slow-growing. (fast-growing pancreato-
biliary type PNI-median 44.9, slow-growing intestinal type PNI-median 47.5, p = 0.032)
Albumin, prealbumin, and transferrin are well known prognostic factors in various kinds
of solid cancer [39–46]. Albumin can be routinely checked and the impact of albumin is
Fig 3. Nomogram to predict the disease-specific survival in resected AoV cancer.
https://doi.org/10.1371/journal.pone.0229597.g003
Table 6. Model performance.
Overall 1-year 3-year 5-year
C-index 95% CI C-index 95% CI C-index 95% CI C-index 95% CI
0.8171 0.7558−0.8737 0.8169 0.6531−0.9643 0.8426 0.7773−0.9024 0.8233 0.7622−0.8812
C-index: <0.5 (very poor model), 0.5 (no better than random change), 0.7−0.8 (good model), >0.8 (strong model), 1 (perfectly predicts a certain outcome).
https://doi.org/10.1371/journal.pone.0229597.t006
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thought to be incorporated in the concept of PNI (albumin (g/dL)×10 + preoperative lympho-
cytic count×0.005). In this study, PNI is currently known as a better factor in reflecting prog-
nosis than albumin. However, our center does not routinely check prealbumin and
transferrin. Therefore, the potential oncologic impact of these factors in managing AoV cancer
needs to be further investigated in near future.
Even though the exact mechanism how PNI affects cancer outcomes is not understood yet,
nowadays researchers are focusing on immunity and nutritional factor [47–50]. It is hypothe-
sized that patients with high PNI may have the appropriate general conditions, as result, they
can be easily presumed to have better compliance at adjuvant treatment, which could make dif-
ference in long term oncologic outcomes. The mechanism of PNI and the way to improve pre-
operative PNI are potential topics to be investigated in the near future by our further studies.
Our study has several limitations. It had a retrospective study design and a limited number
of patients were included. The nomogram developed also needs external validation. Further
study is necessary to reconfirm the potential association between preoperative PNI and long-
term oncological outcomes based on a large study population. In summary, the present study
showed that preoperative PNI was an independent prognostic factor for predicting the long-
term oncological outcomes in resected AoV cancer. This is the first study to show the potential
oncological impact of preoperative PNI in resected AoV cancer, suggesting that improving the
preoperative PNI can result in a positive oncological impact in resected AoV cancer.
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